These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

615 related items for PubMed ID: 25729432

  • 1. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.
    Amiot A, Peyrin-Biroulet L.
    Therap Adv Gastroenterol; 2015 Mar; 8(2):66-82. PubMed ID: 25729432
    [Abstract] [Full Text] [Related]

  • 2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F, Portela F.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228
    [Abstract] [Full Text] [Related]

  • 3. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, Kaplan GG, Bernstein CN, Bitton A, Nguyen GC, Lee K, Cooke-Lauder J, Murthy SK.
    J Can Assoc Gastroenterol; 2019 Feb 14; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, Louis E, Lukáš M, Reinisch W, Roblin X, Jang M, Byun HG, Kim DH, Lee SJ, Atreya R.
    BMC Gastroenterol; 2022 Jun 08; 22(1):291. PubMed ID: 35676620
    [Abstract] [Full Text] [Related]

  • 5. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.
    Rawla P, Sunkara T, Raj JP.
    J Inflamm Res; 2018 Jun 08; 11():215-226. PubMed ID: 29844695
    [Abstract] [Full Text] [Related]

  • 6. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P.
    United European Gastroenterol J; 2015 Oct 08; 3(5):419-28. PubMed ID: 26535119
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.
    Kumar P, Vuyyuru SK, Kante B, Kedia S, Sahu P, Ranjan MK, Mundhra S, Golla R, Kumar M, Virmani S, Gupta A, Yadav N, Makharia G, Ahuja V.
    Indian J Gastroenterol; 2022 Oct 08; 41(5):446-455. PubMed ID: 36378484
    [Abstract] [Full Text] [Related]

  • 8. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
    Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Giorgetti G, Graziani MG, Lofano K, Lorenzetti R, Larussa T, Penna A, Pica R, Pranzo G, Rodino' S, Scarcelli A, Zampaletta C, Bassotti G, Cazzato AI, Chiri S, Clemente V, Cocco A, De' Angelis G, Donnarumma L, Faggiani R, Graziosi C, Le Grazie M, Luzza F, Meucci C, Monterubbianesi R, Pagnini C, Perazzo P, Picchio M, Sacco R, Sebkova L, Serio M, Napolitano D, Pugliese D, Scaldaferri F, Schiavoni E, Turchini L, Armuzzi A, Elisei W, Maconi G, Papa A.
    Inflamm Bowel Dis; 2023 Mar 01; 29(3):376-383. PubMed ID: 35579320
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Biologic targeting in the treatment of inflammatory bowel diseases.
    Bosani M, Ardizzone S, Porro GB.
    Biologics; 2009 Mar 01; 3():77-97. PubMed ID: 19707398
    [Abstract] [Full Text] [Related]

  • 18. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N.
    Aliment Pharmacol Ther; 2015 Nov 01; 42(10):1158-69. PubMed ID: 26365281
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R, Martinez de Zabarte Fernandez JM, Pujol-Muncunill G, Donat-Aliaga E, Segarra-Cantón O, Irastorza-Terradillos I, Medina-Benitez E, Ruiz-Hernández CJ, Carrillo-Palau M, Ros-Arnal I, Rodriguez-Martínez A, Escartin-Madurga L, Gutiérrez-Junquera C, Vicente-Santamaría S, Velasco Rodriguez-Belvis M, Fernández-Fernández S, Alberto-Alonso JR, Montraveta M, Torres-Peral R, Navalon-Rubio M, Navas-López VM, Martin de Carpi J.
    Eur J Pediatr; 2021 Sep 01; 180(9):3029-3038. PubMed ID: 33880650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.